Cargando…

High CD44 expression is not a prognosis marker in patients with high-risk neuroblastoma

Detalles Bibliográficos
Autores principales:	Louis-Brennetot, Caroline, Delattre, Olivier, Janoueix-Lerosey, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083781/ https://www.ncbi.nlm.nih.gov/pubmed/32200273 http://dx.doi.org/10.1016/j.ebiom.2020.102702

Ejemplares similares

Response to “High CD44 expression is not a prognosis marker in patients with high-risk neuroblastoma”
por: Vega, Francisco M., et al.
Publicado: (2020)

Plasticity in Neuroblastoma Cell Identity Defines a Noradrenergic-to-Mesenchymal Transition (NMT)
por: Gautier, Margot, et al.
Publicado: (2021)

Activated ALK signals through the ERK–ETV5–RET pathway to drive neuroblastoma oncogenesis
por: Lopez-Delisle, Lucille, et al.
Publicado: (2018)

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations
por: Durand, Simon, et al.
Publicado: (2019)

HMCan-diff: a method to detect changes in histone modifications in cells with different genetic characteristics
por: Ashoor, Haitham, et al.
Publicado: (2017)

Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis
por: Boeva, Valentina, et al.
Publicado: (2013)

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma
por: Cazes, Alex, et al.
Publicado: (2014)

BET and CDK Inhibition Reveal Differences in the Proliferation Control of Sympathetic Ganglion Neuroblasts and Adrenal Chromaffin Cells
por: Sriha, Jessica, et al.
Publicado: (2022)

Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment
por: Mazot, Pierre, et al.
Publicado: (2012)

Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma
por: Costa, Ana, et al.
Publicado: (2022)

Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma
por: Bellini, Angela, et al.
Publicado: (2019)

Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization
por: Boeva, Valentina, et al.
Publicado: (2011)

Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival
por: Brisse, Hervé J., et al.
Publicado: (2017)

Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma
por: Thirant, Cécile, et al.
Publicado: (2023)

SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data
por: Zeitouni, Bruno, et al.
Publicado: (2010)

High Expression of CD44 Predicts a Poor Prognosis in Glioblastomas
por: Si, Daolin, et al.
Publicado: (2020)

Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data
por: Boeva, Valentina, et al.
Publicado: (2012)

Learning smoothing models of copy number profiles using breakpoint annotations
por: Hocking, Toby Dylan, et al.
Publicado: (2013)

Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN
por: Guimier, Anne, et al.
Publicado: (2014)

Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression.
por: Combaret, V., et al.
Publicado: (1997)

CD44s and CD44v6 Expression in Head and Neck Epithelia
por: Mack, Brigitte, et al.
Publicado: (2008)

SV-Bay: structural variant detection in cancer genomes using a Bayesian approach with correction for GC-content and read mappability
por: Iakovishina, Daria, et al.
Publicado: (2016)

Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma
por: López-Carrasco, Amparo, et al.
Publicado: (2021)

Stem-like and highly invasive prostate cancer cells expressing CD44v8-10 marker originate from CD44-negative cells
por: Di Stefano, Chiara, et al.
Publicado: (2018)

SegAnnDB: interactive Web-based genomic segmentation
por: Hocking, Toby D., et al.
Publicado: (2014)

CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours
por: Vega, Francisco M., et al.
Publicado: (2019)

CD44 Variant Isoform Expression and Breast Cancer Prognosis
por: Tokue, Yutaka, et al.
Publicado: (1998)

Expression of CD44 by rhabdomyosarcoma: a new prognostic marker?
por: Humphrey, G, et al.
Publicado: (1999)

CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis
por: Sosulski, Amanda, et al.
Publicado: (2016)

Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma
por: Tang, Xao X., et al.
Publicado: (2021)

Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes
por: Rombaut, Dries, et al.
Publicado: (2019)

High expression of Dll4 and CD44V6 is associated with clinicopathological characteristics and poor prognosis in osteosarcoma patients
por: Xie, Haiyang, et al.
Publicado: (2021)

Childhood survivors of high‐risk neuroblastoma show signs of immune recovery and not immunosenescence
por: Lázničková, Petra, et al.
Publicado: (2020)

Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells
por: Montavon, Gisèle, et al.
Publicado: (2014)

Expression and clinical significance of colorectal cancer stem cell marker EpCAM(high)/CD44(+) in colorectal cancer
por: LIU, DAN, et al.
Publicado: (2014)

CD44v6 High Membranous Expression Is a Predictive Marker of Therapy Response in Gastric Cancer Patients
por: Almeida, Gabriela M, et al.
Publicado: (2021)

MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment
por: Bartolucci, Damiano, et al.
Publicado: (2022)

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
por: Tucker, Elizabeth R., et al.
Publicado: (2023)

The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
por: Wei, Xiaolei, et al.
Publicado: (2014)

CD44 but not CD24 expression is related to poor prognosis in non-cardia adenocarcinoma of the stomach
por: Cao, Xueyuan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f5lv6e5qrvam082sv0k0365a0v